Related Experiment Video
Updated: Jun 8, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Recent advances in the development of small-molecule CCR5 inhibitors for HIV
Tao Liu1, Zhiyong Weng, Xiaowu Dong
1ZJU-ENS Joint Laboratory of Medicinal Chemistry, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China. lt601@zju.edu.cn
Abstract:
CCR5 (C-C chemokine receptor type 5) is a chemokine receptor that has been identified as a major HIV co-receptor in viral entry and therefore is a highly validated target for the development of new anti-HIV drugs. Here, we discuss the insights gained so far relevant to the development of small-molecule CCR5 inhibitors for the treatment of HIV, and highlight small-molecule CCR5 inhibitors that are currently under preclinical and clinical trials.
More Related Videos
Related Concept Videos
Retrovirus Life Cycles
Inhibitors of Virion Maturation and Assembly
Antiviral Nucleoside Inhibitors
Inhibitors of Viral Protein Synthesis
Inhibitors Of Virion Release

